Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Long term graft survival after renal transplantation varies by primary renal diagnosis and has been correlated with proteinuria (PU). This study of the UK Rare Disease Registry (RaDaR) examines outcomes in patients with primary renal diagnoses of (non-secondary) focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and IgA Nephropathy (IgAN) mapped to proteinuria at 1 year post transplant and to the subsequent control of proteinuria.
RaDaR cohorts were identified with primary diagnoses of idiopathic nephrotic syndrome with biopsy-proven FSGS, MCD and IgAN. 2274 patients were identified who had received a first renal transplant since 2005 and 36% of these had proteinuria data available sufficient to quantify UPCR at 1 year post-transplant. Data extraction occurred on 14/08/2025.
Figure 1 shows Kaplan-Meier plotted outcomes of transplantation (survival without KF, death or eGFR<15) from date of transplant were superior for IgAN to those in FSGS and MCD patients.
Table 1, presenting demography, key characteristics and survival outcomes by diagnosis for patients with PU at 12 months post-transplantation, shows incidence of PU ≥0.3 g/g at this time point in FSGS, MCD and IgAN of 40, 62, 21%, respectively.
Figure 2(A-C) shows transplant survival for the 3 diagnoses stratified by PU ≥ or <0.3g/g at one year post transplantation. In all cases the higher PU group had markedly worse outcomes. The 5 year transplant survival (95% CI) for the higher PU cohorts were 65% (49-77), 66% (56-74) and 59% (27-80) for FSGS, IgAN and MCD respectively.
Figure 3(A,B) shows the KM transplant survival for FSGS and IgAN patients respectively with 12 month PU≥0.3g/g stratified by the control of PU in the subsequent 6-24 months, as lowest value <0.3 or ≥0.3g/g (n values for MCD were too low for this analysis). In both FSGS and IgAN the control of proteinuria after 12 months by this simple metric was associated with better outcomes.
Renal transplant outcomes are better in IgAN patients than those with native diagnoses of FSGS or MCD. This is associated with a lower incidence of PU above 0.3g/g at 12 months. Disease recurrence rates may contribute to these differences. Transplant outcomes in MCD were no better than those in FSGS, despite the younger age of the MCD cohort. For those patients who have PU ≥0.3g/g at 12 months post transplant, outcomes were poor and not correlated with native diagnosis. These data suggest that the development of PU has prognostic significance irrespective of underlying primary glomerular disease. Beyond 12 months, the control of PU appears to be associated with improved outcomes, suggesting the value of interventions that reduce proteinuria.
